Error loading player: No playable sources found

64059

CASSS Welcome & CGTP 2023 Introduction

Date
June 27, 2023
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CGTP Summit 2023 / Cell and Gene Therapy Products Symposium 2023
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…


Related Products

Thumbnail for Parallel Session 2: Product Quality Testing for Individualized Medicines
Parallel Session 2: Product Quality Testing for Individualized Medicines
With the significant progress in the development of individualized medicines, several issues with respect to their routine quality testing have emerged…
Thumbnail for Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Allogeneic cell therapies have a potential to revolutionize life-saving Cell and Gene therapy (CGT) field by removing the bottlenecks created by long scheduling delays, lengthy manufacturing times and potential product failures of autologous cell therapies…
Thumbnail for Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety…
Thumbnail for Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Bringing treatment to those afflicted with an ultra-rare disease is complex. These products are encumbered with challenges ranging from high development costs with a limited ROI, to issues with executing and interpreting clinical trials with unusually small patient populations…